Test Price
2,800 AED✅ Home Collection Available
FBXO7 Gene PARK15 Parkinson Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين FBXO7 (PARK15) لمرض باركنسون بتقنية التسلسل الجيني من الجيل التالي (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي 2026
Executive Summary | الملخص التنفيذي
يقدم هذا التحليل الجيني المتقدم تقييمًا شاملاً لجين FBXO7 المرتبط بمرض باركنسون اليفعي (PARK15) باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS)، وذلك وفقًا لأعلى معايير هيئة الصحة بدبي واللوائح الاتحادية لدولة الإمارات العربية المتحدة لعام 2026.
This advanced NGS-based genetic test delivers a comprehensive assessment of the FBXO7 gene, the established causative locus for PARK15 juvenile-onset parkinsonism. Processed exclusively within our ISO 9001:2015-certified genomic facility (Cert: INT/EGQ/2509DA/3139), this assay provides neurologists, clinical geneticists, and medical researchers with definitive molecular confirmation for differential diagnosis of early-onset movement disorders.
Clinical Overview: FBXO7 PARK15 Genetic Test
The FBXO7 gene, located on chromosome 22q12.3, encodes the F-box only protein 7, a critical component of the ubiquitin-proteasome system implicated in mitochondrial maintenance and dopaminergic neuron survival. Pathogenic biallelic variants in FBXO7 cause autosomal recessive juvenile-onset parkinsonism (PARK15), characterized by early pyramidal signs, levodopa-responsive parkinsonism, and progressive motor deterioration. يرتبط جين FBXO7 بمرض باركنسون اليفعي الموروث بصورة جسدية متنحية، ويُعد هذا التحليل الجيني أداة تشخيصية حاسمة لتأكيد الإصابة وتوجيه خطة العلاج.
This test employs Next-Generation Sequencing (NGS) with complete coding region coverage of FBXO7, including all exons and exon-intron boundaries (±20 bp), achieving >99.5% analytical sensitivity for single nucleotide variants, small insertions/deletions, and copy number variations at a minimum read depth of 100×.
| Parameter | Our FBXO7 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity — Full Gene Coverage | ~95% — Limited to Targeted Exons Only |
| Methodology | NGS (Next-Generation Sequencing) with CNV Analysis | Bidirectional Sanger Sequencing — No CNV Detection |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks (Multi-Exon Sequential Analysis) |
| Sample Flexibility | Whole Blood, Extracted DNA, or Dried Blood Spot (FTA Card) | Whole Blood or Extracted DNA Only |
| Clinical Reporting | Comprehensive — ACMG Variant Classification, Clinical Correlation, Cascade Screening Guidance | Basic — Variant Call with Minimal Interpretation |
| UAE Regulatory Compliance | Full — DHA, MOHAP, ISO 9001:2015, Federal Decree-Law No. 41/2024 | Variable — Often Lacks UAE-Specific Accreditation |
Physician Insight & Clinical Safety Protocol
"As a neurologist practicing in the UAE, I emphasize that the FBXO7 PARK15 NGS test is a powerful molecular diagnostic tool, yet it must always be interpreted within the complete clinical context — including neurological examination findings, neuroimaging results, and family history. A positive result confirms the genetic subtype and guides personalized management, while a negative result does not exclude other forms of parkinsonism. I strongly urge every patient to discuss results with their treating neurologist or a qualified clinical geneticist before making any therapeutic decisions."
— Dr. Prabhakar Reddy, DHA License No. 61713011, Consultant Neurologist & Genomic Medicine Specialist
Critical Medication Advisory
Do not discontinue, modify, or adjust the dosage of any prescribed medication — including levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, or any antiparkinsonian therapy — without consulting your treating physician. Abrupt withdrawal of dopaminergic medications may precipitate neuroleptic malignant-like syndrome, severe rigidity, or life-threatening autonomic instability.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed If:
- Patient is under 18 years of age without court-appointed guardian consent (CDS Law 2026, Minors).
- Inability to provide valid UAE Emirates ID or passport for identity verification.
- Active febrile illness or acute infection at time of sample collection — reschedule after recovery.
- Recent blood transfusion (within 4 weeks) — may confound germline DNA analysis.
- Absence of documented clinical indication or specialist referral as required under Federal Decree-Law No. 41 of 2024 (Art. 87).
Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden worsening of motor symptoms with confusion or altered consciousness.
- Severe muscle rigidity with hyperthermia — possible neuroleptic malignant-like syndrome.
- Acute respiratory distress or aspiration pneumonia.
- Psychotic symptoms, hallucinations, or severe impulse control disorder.
- Unexplained falls with head trauma in parkinsonian patients.
Pre-Test Requirements & Genetic Counseling Mandate
- A comprehensive clinical history must be provided, including age at onset, initial motor symptoms (tremor, rigidity, bradykinesia), response to levodopa therapy, and presence of pyramidal signs.
- A pre-test genetic counseling session is mandatory to construct a detailed three-generation pedigree chart documenting all family members affected with parkinsonism, neurological disorders, or unexplained gait disturbances.
- Informed consent must be obtained after full disclosure of the test's diagnostic yield, potential incidental findings, implications for family members, and data privacy protections under UAE PDPL.
- Fasting is not required. The patient may continue all prescribed medications unless specifically directed otherwise by their physician.
- Acceptable sample types: Whole Blood (3-5 mL in EDTA tube), Extracted DNA (minimum 1 μg at ≥50 ng/μL), or One Drop Blood on FTA Card (allowed for pediatric/minor patients and remote collections).
- Sample must be collected by a DHA-licensed phlebotomist and transported via ISO-certified cold-chain logistics at 2-8°C within 24 hours of venipuncture.
Frequently Asked Questions — Patient & Family Guidance
What is the FBXO7 PARK15 Genetic Test, and why is it clinically recommended?
The FBXO7 PARK15 NGS test is a high-precision molecular diagnostic assay that detects pathogenic mutations in the FBXO7 gene responsible for autosomal recessive juvenile-onset Parkinson's disease with 99.9% diagnostic sensitivity. Clinically, it is recommended for patients presenting with early-onset parkinsonism (before age 40), particularly those exhibiting pyramidal tract signs, levodopa-responsive motor symptoms, and a positive family history suggesting autosomal recessive inheritance. Definitive genetic confirmation enables personalized treatment planning, prognostic counseling, and cascade screening of at-risk family members to identify pre-symptomatic carriers.
يكتشف اختبار FBXO7 PARK15 NGS الطفرات الجينية المسببة لمرض باركنسون اليفعي الموروث بصورة جسدية متنحية، ويُوصى به سريريًا للمرضى الذين تظهر عليهم أعراض باركنسونية قبل سن الأربعين، خاصةً مع وجود علامات هرمية وتاريخ عائلي إيجابي. يتيح التأكيد الجيني وضع خطة علاجية مخصصة وتقديم المشورة الوراثية لأفراد الأسرة المعرضين للخطر.
How is the FBXO7 PARK15 Genetic Test performed, and what is the sample collection process in the UAE?
A DHA-licensed phlebotomist performs a simple, virtually painless venous blood draw (3-5 mL) during a scheduled home visit, or alternatively a single-drop blood spot on an FTA card is collected for pediatric and remote-area patients, with all samples transported under ISO-certified cold-chain to our genomic laboratory for NGS analysis with a 3-to-4-week turnaround. The home collection service operates daily from 8 AM to 11 PM across all seven emirates, ensuring maximum convenience for patients with mobility challenges. Once the sample arrives at our facility, DNA is extracted, quantified, and subjected to targeted NGS enrichment covering the entire FBXO7 coding region, followed by bioinformatics analysis aligned to the GRCh38/hg38 reference genome and variant classification per ACMG/AMP 2026 guidelines.
يتم سحب عينة دم وريدي بسيطة (3-5 مل) على يد فني معتمد من هيئة الصحة بدبي خلال زيارة منزلية مجدولة، أو بديلاً عنها بقعة دم على بطاقة FTA للمرضى الأطفال والمناطق النائية، مع نقل جميع العينات تحت سلسلة تبريد معتمدة بمواصفة ISO إلى مختبرنا الجيني لتحليلها بتقنية NGS خلال 3 إلى 4 أسابيع.
What do the FBXO7 PARK15 genetic test results mean for my long-term health and family planning?
A positive (pathogenic/likely pathogenic) FBXO7 result confirms PARK15-linked juvenile parkinsonism, guiding neurologists toward optimized levodopa and adjunctive therapy while prompting genetic counseling for family members regarding autosomal recessive inheritance with a 25% recurrence risk in future pregnancies. A negative result rules out FBXO7 as the causative gene but does not exclude other genetic or idiopathic forms of parkinsonism, necessitating continued neurological follow-up and potential broader panel testing or whole-exome sequencing. Variants of uncertain significance (VUS) require periodic reclassification as new scientific evidence emerges, and family segregation studies may be recommended to clarify pathogenicity. All results are disclosed through a structured genetic counseling session to ensure psychological preparedness and informed decision-making regarding reproductive options, including preimplantation genetic testing if desired.
تؤكد النتيجة الإيجابية لجين FBXO7 تشخيص باركنسون PARK15 اليفعي وتوجه الأطباء نحو العلاج الأمثل، مع تقديم المشورة الوراثية للعائلة حول نمط الوراثة الجسدية المتنحية وخطر تكرار الإصابة بنسبة 25% في الأحمال المستقبلية. النتيجة السلبية لا تستبعد الأشكال الأخرى من الباركنسونية وتستوجب متابعة عصبية مستمرة.
UAE Regulatory Compliance & Data Privacy Assurance
Federal Decree-Law No. 41 of 2024 (Art. 87)
Strict adherence to genetic testing regulations including mandatory informed consent, pre- and post-test counseling requirements, and prohibition of genetic discrimination in insurance and employment within the UAE.
CDS Law 2026 — Minor Protection
Genetic testing of minors requires court-appointed guardian authorization. All pediatric samples processed exclusively under stringent ethical protocols with family-centered counseling.
UAE PDPL — Genomic Data Privacy
All genomic data is encrypted, stored on UAE-sovereign servers, and never shared with third parties without explicit consent. Full compliance with UAE Personal Data Protection Law.
ISO 9001:2015 Certification: Cert: INT/EGQ/2509DA/3139 — Quality Management System audited annually. Facility License: 9834453 — DHA/MOHAP Registered Genomic Testing Facility.
Relevant Clinical Specialists
Neurologist
Primary specialist for PARK15 diagnosis, motor symptom evaluation, and treatment management.
Clinical Geneticist
Genetic counseling, pedigree analysis, variant interpretation, and family cascade screening.
Medical & PhD Researcher
FBXO7 functional studies, genotype-phenotype correlation, and academic collaboration.
Book Your FBXO7 PARK15 Genetic Today
Home Collection Available | 3-4 Weeks TAT | ISO-Certified | 2800 AED
Support available daily 8 AM – 11 PM | DHA Facility License: 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians